Circulation. 2003;108:492-497
doi: 10.1161/01.CIR.0000078349.43742.8A
doi: 10.1161/01.CIR.0000078349.43742.8A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:492.)
© 2003 American Heart Association, Inc.
Cardiovascular Drugs |
Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward?
Part II: Chronic Inotropic Therapy
From the Division of Cardiology, Brigham and Women’s Hospital, Boston, Mass.
Correspondence to Lynne Warner Stevenson, MD, Division of Cardiology, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115.
Key Words: heart failure • cardiomyopathy • hemodynamics
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
 |
Introduction |
|---|
Therapy with intravenous inotropic agents is most often initiated as short-term therapy during hospitalization to achieve one of several goals for acute management of decompensation, as described in part I of this report (Table).1 However, it may become difficult to wean these infusions in some patients as a heart failure progresses to late stages.
|
|
Chronic Inotropic Infusions as Bridging Therapy |
|---|
Identification of Inotrope Dependence
Many considered initially to be dependent on inotropic infusions can undergo successful weaning after complete diuresis of excess volume and careful adjustment of concomitant oral medications, which may be facilitated by hemodynamic monitoring to optimize loading conditions on oral agents.2,3 ß-Adrenergic receptor antagonists would have been discontinued already in most cases. ACE inhibitors may need to be discontinued to maximize blood pressure and renal function, with addition of nitrates with or without hydralazine as needed for vasodilation. Dependence should not be declared until multiple interventions and weaning attempts have been made, in most cases requiring 2 to 3 weeks in the hospital, a systematic approach discussed by Hershberger et al.3
Although its magnitude can be debated, there is clearly a population of patients who are considered by experienced heart failure teams to be dependent on intravenous inotropic infusions despite multiple weaning attempts.4 It is assumed that such patients would not survive hospital discharge without ongoing inotropic support, although consensus has not been reached on exactly who they are. Dependence is most often manifested as symptomatic hypotension, recurrent congestive symptoms, or worsening renal function early
This article has been cited by other articles:
 |
|
 |
|
  M. Kato, S. Sanada, and M. Kitakaze Should We Use Outpatient Dobutamine or Milrinone? Circ Heart Fail, July 1, 2009; 2(4): 377 - 378. [Full Text] [PDF]
|
|
|
|
|
|
E. Z. Gorodeski, E. C. Chu, J. R. Reese, M. H. Shishehbor, E. Hsich, and R. C. Starling Prognosis on Chronic Dobutamine or Milrinone Infusions for Stage D Heart Failure Circ Heart Fail, July 1, 2009; 2(4): 320 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Overgaard and V. Dzavik Inotropes and Vasopressors: Review of Physiology and Clinical Use in Cardiovascular Disease Circulation, September 2, 2008; 118(10): 1047 - 1056. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sakata, D. Lebeche, N. Sakata, Y. Sakata, E. R. Chemaly, L. F. Liang, Y. Takewa, D. Jeong, W. J. Park, Y. Kawase, et al. Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2356 - H2363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hambleton, H. Hahn, S. T. Pleger, M. C. Kuhn, R. Klevitsky, A. N. Carr, T. F. Kimball, T. E. Hewett, G. W. Dorn II, W. J. Koch, et al. Pharmacological- and Gene Therapy-Based Inhibition of Protein Kinase C{alpha}/{beta} Enhances Cardiac Contractility and Attenuates Heart Failure Circulation, August 8, 2006; 114(6): 574 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Stevenson and E. Lewis Mapping the Journey J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1612 - 1614. [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson and P. Shekar Ventricular Assist Devices for Durable Support Circulation, August 30, 2005; 112(9): e111 - e115. [Full Text] [PDF]
|
|
|
|
|
|
M. Hayase, F. del Monte, Y. Kawase, B. D. MacNeill, J. McGregor, R. Yoneyama, K. Hoshino, T. Tsuji, A. M. De Grand, J. K. Gwathmey, et al. Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2995 - H3000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. Stevenson Design of therapy for advanced heart failure Eur J Heart Fail, March 16, 2005; 7(3): 323 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson, L. W. Miller, P. Desvigne-Nickens, D. D. Ascheim, M. K. Parides, D. G. Renlund, R. M. Oren, S. K. Krueger, M. R. Costanzo, L. S. Wann, et al. Left Ventricular Assist Device as Destination for Patients Undergoing Intravenous Inotropic Therapy: A Subset Analysis From REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure) Circulation, August 24, 2004; 110(8): 975 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Z. Pantilat and A. E. Steimle Palliative Care for Patients With Heart Failure JAMA, May 26, 2004; 291(20): 2476 - 2482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. del Monte, D. Lebeche, J. L. Guerrero, T. Tsuji, A. A. Doye, J. K. Gwathmey, and R. J. Hajjar From the Cover: Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling PNAS, April 13, 2004; 101(15): 5622 - 5627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|